US2009018183A1PendingUtilityA1
N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
Est. expiryAug 6, 2021(expired)· nominal 20-yr term from priority
A61P 7/00A61P 3/10A61P 3/04A61P 35/00A61P 9/00A61P 43/00A61P 35/04A61P 37/08A61P 9/10A61P 5/00A61P 25/02A61P 25/18A61P 29/00A61P 25/04A61P 25/28A61P 3/00A61P 25/00A61P 1/14A61P 15/00A61P 17/16A61P 17/00A61P 15/08C07D 207/36C07D 207/38C07D 207/34C07D 207/42C07D 207/335
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH 2 ) n where n is 0, 1 or 2; R 1 , R 2 , R 3 , R 4 and R 5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R 1 , R 2 , R 3 , R 4 and R 5 may together form a methylenedioxy or ethylenedioxy moiety; R 6 , R 7 , R 8 and R 9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.
Claims
exact text as granted — not AI-modified1 - 59 . (canceled)
60 . A method of treating a disease associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones, comprising the use or administration of an effective amount of a compound of I formula (I), or tautomeric forms thereof:
wherein X is (CH 2 ) n where n is 0, 1 or 2;
R 1 , R 2 , R 3 , R 4 and R 5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho and any of the following structures:
and/or two of R 1 , R 2 , R 3 , R 4 and R 5 may together form a methylenedioxy or ethylenedioxy moiety;
R 6 , R 7 , R 8 and R 9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; or a pharmaceutically acceptable salt thereon, in a pharmaceutically acceptable carrier
61 . The method as claimed in claim 60 , wherein in the compound of formula I, at least two of the substituents R 1 , R 2 , R 3 , R 4 and R 5 are hydrogen.
62 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein alkyl is methyl, ethyl, n-butyl, n-pentyl or tert-butyl.
63 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein alkoxy is methoxy, ethoxy, propyloxy, butoxy or tert-butoxy.
64 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein R 6 , R 7 and R 8 are hydrogen.
65 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein halogen is selected from fluoro, chloro or bromo.
66 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein n=0.
67 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein R 5 is hydrogen.
68 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein R 3 is hydrogen.
69 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein R 4 is hydrogen.
70 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein the —X—CH═N—NH—C(═NH)—NH 2 moiety is in the 2 position of the pyrrole ring.
71 . The method as claimed in claim 60 , wherein in the compound of formula I, wherein R 1 and R 2 are positioned in the 3, 4 or 5 position in the phenyl ring.
72 . The method as claimed in claim 60 , wherein in the compound of formula I, is
No.
Name
1
N-{1-[(4-Chlorophenyl)-1H-Pyrrol-2-
yl]methyleneamino}guanidine
2
N-[1-(5-propylamino-1-(2-butoxyphenyl)-1H-pyrrol-2-yl)-
methyleneamino]-guanidine
3
N-{3-[1-(2-Isobutyrylphenyl)-5-nitro-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
4
N-{1-[1-(3-Cyanophenyl)-5-trifluoromethyl-1H-pyrrol-2-yl]-
methyleneamino}-guanidine
5
N-{3-[1-(3-Fluorophenyl)-5-methyl-1H-pyrrol-3-yl]-
propylideneamino}-guanidine
6
N-[1-(4-Aminophenyl)-5-hydroxy-1H-pyrrol-2-
ylmethylideneamino]-guanidine
7
N-{3-[1-(4-Chlorophenyl)-5-phenethyl-1H-pyrrol-3-yl]-
propylideneamino}-guanidine
8
N-{3-[1-(4-Propylaminophenyl)-5-trichloromethyl-1H-pyrrol-3-
yl]-propylideneamino}-guanidine
9
N-(5-tert-Butyl-1-phenyl-1H-pyrrol-2-ylmethylideneamino)-
guanidine
10
N-[3-(5-Methoxy-1-phenyl-1H-pyrrol-3-yl)-propylideneamino]-
guanidine
11
N-[4-Pentyl-1-(2-trichloromethylphenyl)-1H-pyrrol-3-
ylmethylideneamino]-guanidine
12
N-(4-Cyano-1-o-tolyl-1H-pyrrol-3-ylmethylideneamino)-
guanidine
13
N-{3-[4-Hydroxy-1-(3-trichloromethylphenyl)-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
14
N-{3-[1-(3-tert-Butylphenyl)-5-isobutyryl-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
15
N-(1-Biphenyl-4-yl-4-chloro-1H-pyrrol-2-ylmethylideneamino)-
guanidine
16
N-{3-[1-(4-Bromophenyl)-4-tert-butyl-1H-pyrrol-3-yl]-
propylideneamino}-guanidine
17
N-(4-Butoxy-1-phenyl-1H-pyrrol-3-ylmethylideneamino)-
guanidine
18
N-[3-(4-Methoxy-1-phenyl-1H-pyrrol-2-yl)-propylideneamino]-
guanidine
19
N-{3-[1-(2-Nitrophenyl)-1H-pyrrol-2-yl]-propylideneamino}-
guanidine
20
N-{3-[1-(2-Hydroxyphenyl)-1H-pyrrol-2-yl]-propylideneamino}-
guanidine
21
N-[1-(3-Methoxyphenyl)-1H-pyrrol-2-ylmethylideneamino]-
guanidine
22
N-[1-(3-Butylaminophenyl)-1H-pyrrol-3-ylmethylideneamino]-
guanidine
23
N-[1-(4-tert-Butylphenyl)-1H-pyrrol-3-ylmethylideneamino]-
guanidine
24
N-{3-[1-(4-Trifluoromethylphenyl)-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
25
N-(1-Phenyl-1H-pyrrol-3-ylmethylideneamino)-guanidine
26
N-[3-(1-Phenyl-1H-pyrrol-2-yl)-propylideneamino]-guanidine
29
N-[3-(4-Methyl-1-phenyl-1H-pyrrol-3-yl)-propylideneamino]-
guanidine
30
N-[1-(3-Nitro-4-propylaminophenyl)-1H-pyrrol-3-
30
ylmethylideneamino]-guanidine
31
N-{3-[1-(3-Butylamino-4-methyl-phenyl)-4-methyl-1H-pyrrol-2-
31
yl]-propylidene}-guanidine
32
N-{3-[5-Bromo-1-(4-bromophenyl)-1H-pyrrol-3-yl]-
propylideneamino}-guanidine
33
N-[(5-Chloro-1-(4-isobutyrylphenyl)-4-pentyl-1H-pyrrol-2-
yl)methyleneamino]-guanidine
34
N-[3-(5-Propoxy-1-m-tolyl-1H-pyrrol-2-yl)-propylideneamino]-
guanidine
35
N-[4-Methyl-5-propylamino-1-(3-trichloromethyl-phenyl)-1H-
pyrrol-3-ylmethylideneamino]-guanidine
36
N-{3-[1-(3-Nitro-biphenyl-4-yl)-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
37
N-{2-[4-tert-Butyl-1-(4-methoxy-2-propylaminophenyl)-1H-
pyrrol-3-yl]-ethylideneamino}-guanidine
38
N-{3-[1-(2-Bromo-3-chlorophenyl)-1H-pyrrol-3-yl]-
propylideneamino}-guanidine
39
N-[4-Bromo-1-(2-butoxy-3-propoxyphenyl)-1H-pyrrol-2-
ylmethylideneamino]-guanidine
40
N-[5-Hydroxy-1-(2-hydroxyphenyl)-1H-pyrrol-3-
ylmethylideneamino]-guanidine
41
N-{3-[1-(2-tert-Butylphenyl)-4-chloro-5-methyl-1H-pyrrol-2-yl]-
propylideneamino}-guanidine
42
N-[5-lsobutyryl-1-(2,3,4-trimethoxyphenyl)-1H-pyrrol-2-
ylmethylideneamino]-guanidine
43
N-{3-[5-tert-Butyl-1-(2-tert-butyl-3,4-bis-trichloromethylphenyl)-
4-trichloromethyl-1H-pyrrol-2-yl]-propylideneamino}-guanidine
44
N-{2-[1-(4-Pyrrol-1-ylphenyl)-1H-pyrrol-2-yl]-ethylideneamino}-
guanidine
45
N-[1-(4-Morpholin-4-ylphenyl)-1H-pyrrol-2-
ylmethylideneamino]-guanidine
46
N-[1-(4-Pyrrolidin-1-ylphenyl)-1H-pyrrol-3-ylmethylidenamino]-
guanidine
47
N-((1-Phenyl-1H-pyrrol-2-yl)methyleneamino)guanidine
48
N-[(1-(4-Trifluoromethylphenyl)-1H-pyrrol-2-
yl)methyleneamino]guanidine
49
N-[(1-(3-cyanophenyl)-1H-pyrrol-2-
yl)methyleneamino]guanidine
50
N-[(1-(3,5-dichlorophenyl)-1H-pyrrol-2-
yl)methyleneamino]guanidine
or a pharmacologically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.